Aerie Pharmaceuticals — Technical Presentation (November 2019)
8 slides from Aerie Pharmaceuticals's technical presentation, Nov 6, 2019
Slide 1: AR-13324-CS208 Japan Phase 2 Study Topline Results
AR-13324-CS208 Japan Phase 2 Study Topline Results November 6, 2019 Exhibit 99.1
Slide 2: Important Information
Important Information The information in this presentation is current only as of its date and may have changed or may change in the future. We are not making any representation or warranty that the information in this presentation is accurate or complete. Certain statements in this presentation are
Slide 3: Japan Phase 2 Executive Summary
Japan Phase 2 Executive Summary 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious and met primary endpoint of
Slide 4: Study Design and Primary Endpoints
Primary Endpoints Efficacy: Mean diurnal IOP at Week 4 Safety: Ocular/Systemic safety during a 4-week treatment period Japanese patients with Open Angle Glaucoma (OAG) with IOP (unmedicated) ≥ 15 mmHg and < 35 mmHg or Ocular Hypertension (OHT) with IOP (unmedicated) ≥ 22 mmHg and < 35 mmHg N = 215 s
Slide 5: Efficacy – Mean IOP at Each Time Point
Efficacy – Mean IOP at Each Time Point For Investor Use
Slide 6: Primary Endpoint – Mean Diurnal IOP
Primary Endpoint – Mean Diurnal IOP P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation For Investor Use
Slide 7: Treatment-Emergent Adverse Events and Safety Summary
Any TEAEs ≥ 2% System Organ Class Preferred Term Netarsudil 0.01% QD (N=55) n (%) Netarsudil 0.02% QD (N=54) n (%) Netarsudil 0.04% QD (N=51) n (%) Placebo (N=55) n (%) Eye Disorders 16 ( 29.1) 22 ( 40.7) 32 ( 62.7) 3 ( 5.5) Conjunctival hyperemia 13 ( 23.6) 20 ( 37.0) 29 ( 56.9) 1 ( 1.8) Eye irrita
Slide 8: Executive Summary
Japan Phase 2 Executive Summary Netarsudil 0.01%, 0.02% and 0.04% were efficacious and met primary endpoint of superiority to placebo in mean diurnal IOP1 Baseline mean diurnal IOPs were 20 - 21 mmHg across study arms2 Week 4 mean diurnal IOP was 16.3 (-4.1), 15.4 (-4.8), 16.2 (-4.8) and 19.3 (-1.7)
Aerie Pharmaceuticals — Technical Presentation (November 2019) on 6ix